‘Large' fanged creature found behind a trapdoor in India. It's a new species
Scientists dug around the trapdoor to catch the bristly animal — and discovered a new species.
A team of researchers hiked along the 'outskirts of Kalakad-Mundanthurai Tiger Reserve' in May 2021 as part of a regionwide survey of scorpions, spiders and other arachnids, according to a study published May 26 in the peer-reviewed journal Taprobanica.
During a morning search of the 'savanna grassland habitat,' researchers noticed some burrows and trapdoors in the 'reddish, gravelly soil,' the study said. Intrigued, they opened the doors, watched the spiders that momentarily emerged and began 'carefully' digging up the burrows.
Researchers eventually caught roughly a dozen of these spiders and, after taking a closer look, realized they'd discovered a new species: Heligmomerus australis, or the southern trapdoor spider.
Southern trapdoor spiders are considered 'large-sized,' reaching over an inch across, the study said. They have bristly bodies, claws, fangs and eight eyes arranged 'in three rows.'
Photos show the reddish brown coloring of the new species.
Southern trapdoor spiders built 'large' and 'deep' burrows with 'a single entrance,' the study said. These entrances were covered with a round, 'fairly thick' door constructed with silk, 'dried grass and algae, sand particles, and grass leaves.'
While excavating one burrow, researchers found 'two spiderlings along with an adult female.'
Researchers said they named the new species after the Latin word for 'south' because the site where it was discovered is 'currently the southernmost known locality for the genus Heligmomerus on the Indian peninsula.'
So far, southern trapdoor spiders have only been found at one site around Kalakad-Mundanthurai Tiger Reserve in Tamil Nadu near the southernmost tip of mainland India and a roughly 1,700-mile drive south from New Delhi.
The new species was identified by its reproductive system, eye shape and arrangement, body shape and other subtle physical features, the study said. Researchers did not provide a DNA analysis of the new species.
The research team included Akshay Khandekar, Tejas Thackeray, Swapnil Pawar, Vivek Waghe and Satpal Gangalmale.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
13 hours ago
- Medscape
Fish Bone or Cancer? 80-Year-Old's Perforation Case
Key Takeaways An 80-year-old man presented with progressive lower left-quadrant abdominal pain. Imaging studies identified a mass adjacent to the sigmoid colon, with features suggestive of an abscess, although no definitive foreign body was detected preoperatively. Surgical exploration revealed a sigmoid colon perforation associated with a sharp foreign object, which was later confirmed to be a fish bone. Histopathological examination revealed an inflammatory response without evidence of malignancy. The case reported by Daniel Herrera Hernández, MD, and colleagues from the Hospital General Regional No. 1 Instituto Mexicano del Seguro Social, Tijuana, Mexico, highlighted a rare cause of intestinal perforation. The Patient and His History The patient had a medical history of diabetes mellitus and hypertension. There was no prior surgical history or screening colonoscopy. He reported a 12-day history of lower left-quadrant abdominal pain, progressively worsening to become intolerable, prompting emergency admission. Findings and Diagnosis On presentation, the patient was stable but exhibited abdominal distension and tenderness on palpation of the left hemiabdomen, without signs of peritoneal irritation. Laboratory tests showed leucocytosis of 20,800/μL (4000-11,000), neutrophils at 65.1% (40%-70%) of total leukocytes, and a serum creatinine of 1.0 mg/dL (0.6-1.2). Abdominal and pelvic CT scans revealed a mass adjacent to the descending colon with peripheral enhancement dependent on the colonic wall, extending into the muscular layer, suggestive of an abscess, as well as a small radio-opaque object in the middle of the phlegmon, supportive of a foreign body. Adjacent fat stranding and free fluid were observed in the left iliac fossa. The patient underwent exploratory laparotomy, revealing a colonic perforation at the sigmoid colon with firm adhesions to the abdominal wall. A sharpened foreign body, approximately 2 cm in length, was found at the adhesion site, which was the cause of the perforation. No diverticula were identified in the colon. Left hemicolectomy with transverse colon terminal colostomy was performed. Postoperative recovery was uneventful under antibiotic therapy with meropenem and metabolic management. The patient was discharged on postoperative day 5 with clinical improvement. The histopathology report indicated chronic inflammation with no evidence of malignancy. Discussion 'Intestinal perforation by a fish bone in the colon is a rare complication that poses diagnostic challenges. It requires a high index of suspicion from surgeons or emergency physicians. In patients with risk factors, such perforations can resemble tumours with abscess formation or perforation secondary to malignancy,' the authors wrote. This story was translated from Univadis Germany.
UPI
a day ago
- UPI
Researchers suggest conch shell blowing as sleep apnea treatment
Regularly blowing through a conch shell for six months significantly improved sleep among a small group of people with sleep apnea, researchers in India found. Photo by Kitreel/Adobe Stock/HealthDay News Want to ease your sleep apnea and get a better night's sleep? Blow through a conch shell, a new pilot clinical trial says. Regularly blowing through a conch shell for six months, like Disney princess Moana or Anchorman legend Ron Burgundy, significantly improved sleep among a small group of people with sleep apnea. Patients blowing a conch slept better, felt more alert during the day and had fewer breathing interruptions at night, researchers reported. Conch blowing might prove a reasonable alternative to using a continuous positive air pressure machine, in which a face mask blows air to keep a patient's airways open while sleeping, said lead researcher Dr. Krishna Sharma, director and head of pulmonology at the Eternal Heart Care Center and Research Institute in Jaipur, India. While CPAP is the gold standard treatment for sleep apnea, many patients find it uncomfortable and noisy. "For people living with obstructive sleep apnea, especially those who find CPAP uncomfortable, unaffordable, or inaccessible, our findings offer a promising alternative," Sharma said in a news release. "[Conch] blowing is a simple low-cost, breathing technique that could help improve sleep and reduce symptoms without the need for machines or medication." Blowing a conch shell, also called shankh blowing, has been part of Indian culture for thousands of years, he explained. "In my clinical practice, several patients reported feeling more rested and experiencing fewer symptoms after regularly practicing shankh blowing - a traditional yogic breathing exercise involving exhaling through a conch shell," Sharma said. Based on these anecdotes, Sharma and colleagues designed a small clinical trial to see if the simple, ancient practice might help people with sleep apnea. In sleep apnea, a person stops breathing repeatedly during the night because their airway collapses, causing them to wake. Sleep apnea patients often snore loudly, and have a higher risk of high blood pressure, heart disease and stroke. Researchers think conch blowing might help by exercising the muscles of the airway. "The way the shankh is blown is quite distinctive. It involves a deep inhalation followed by a forceful, sustained exhalation through tightly pursed lips," Sharma said. "This action creates strong vibrations and airflow resistance, which likely strengthens the muscles of the upper airway, including the throat and soft palate -- areas that often collapse during sleep in people with obstructive sleep apnea," he continued. "The shankh's unique spiraling structure may also contribute to specific acoustic and mechanical effects that further stimulate and tone these muscles." Researchers recruited 30 people with moderate sleep apnea and randomly assigned 16 to practice blowing through a conch shell. The other 14 were taught a deep breathing exercise. All participants were encouraged to practice either conch blowing or deep breathing for a minimum of 15 minutes a day, five days a week. After six months, the people armed with conch shells were 34% less sleepy during the daytime than those practicing deep breathing, results show. They also reported better sleep. Sleep lab tests showed that those blowing a conch shell experienced on average four to five fewer episodes during the night in which they breathing stopped during sleep, as well as higher oxygen levels during sleep. "This is a small study, but we are now planning a larger trial involving several hospitals," Sharma said. "This next phase will allow us to validate and expand on our findings in a broader, more diverse population and assess how shankh blowing performs over longer periods." Future studies also will test to see how conch blowing affects the muscle tone of the airways, and compare the practice directly against standard treatments like CPAP, Sharma said. Sophia Schiza, head of the European Respiratory Society's group on sleep-disordered breathing, reviewed the findings. She said conch blowing might fill a need for more treatments for sleep apnea. "This is an intriguing study that shows the ancient practice of shankh blowing could potentially offer an obstructive sleep apnea treatment for selected patients by targeting muscles training," Schiza said in a news release. "A larger study will help provide more evidence for this intervention which could be of benefit as a treatment option or in combination with other treatments in selected obstructive sleep apnea patients," added Schiza, a professor of pulmonology and sleep disorders at the University of Crete in Greece. The new study appears in the journal ERJ Open Research. More information Johns Hopkins Medicine has more on sleep apnea. Copyright © 2025 HealthDay. All rights reserved.
Business Wire
a day ago
- Business Wire
Vyome Announces New Board of Directors with Deep MIT and AI Ties
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ: RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Holdings, Inc. post-closing and trade under the ticker symbol HIND. The new Vyome board members, which include four Massachusetts Institute of Technology (MIT) alums, are all persons with prior board or executive management experience and are based in the US while having deep ties to the Indian subcontinent and the latest advances in AI. "We are offering RSLS shareholders significant potential value, and no member of the ReShape board or its management team has been invited to join Vyome Holdings. It is critical to have a board that is fully aligned with all shareholders, and that's the board we have taking over on Friday. We have a massive vision with a clean company at close – no debt, no toxic structure, all major shareholders locked up, and a world-class team which we look forward to sharing more about in the coming days and weeks," said Krishna Gupta, Chairman of Vyome Holdings. The Vyome board will include the following individuals: Krishna Gupta (Chairman), MIT engineering/business alum and CEO of Remus Capital - very focused on Vertical AI, applying AI into large traditional industries, including healthcare. He has spent extensive time doing business across India, having been to 22 of its 36 states and union territories. Shiladitya Sengupta (Founder), MIT postgrad - serial entrepreneur and reputed professor/researcher at MIT and Harvard Medical School focused on the intersection of medicine and engineering. He was a gold medalist at India's top medical university (AIIMS). Venkat Nelabhotla (Co-founder and CEO), IIM Ahmedabad alum - a seasoned operator with 30+ years of success across pharma, biotech, and CPG industries. He has been a CEO of Emami Limited - a publicly listed company in India, and during his tenure played a pivotal role in significantly increasing the market cap. Mohanjit Jolly (Shareholder), MIT alum and Partner of Iron Pillar – a seasoned investor and board member for cutting-edge technology companies. He has been investing in India for nearly 20 years. John Tincoff (Shareholder), Georgetown alum, Partner at Remus Capital - has a deep focus on industrial applications with extensive governance experience. He co-manages Remus Capital and leads its industrial AI investing practice, while also having significant board experience across verticals. He spent many years living in South Asia, including significant experience in India. Stash Pomichter (Shareholder), MIT engineering dropout and is a member of the Remus Capital team - has a deep focus on cutting-edge AI applications from voice to robotics. He grew up in India. About Vyome Therapeutics Vyome Therapeutics is building a healthcare platform spanning the US-India innovation corridor. Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. Based in Cambridge, MA, the company has announced its intent to be listed on the Nasdaq exchange under the ticker 'HIND' pursuant to a reverse merger with ReShape Lifesciences Inc. (Nasdaq: RSLS) in early 2025. To learn more, please visit Visit us on social media: Facebook X LinkedIn Forward-Looking Statements Certain statements made in this press release are 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'target,' 'believe,' 'expect,' 'will,' 'shall,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' 'forecast,' 'intend,' 'plan,' 'project,' 'outlook', and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made in this report regarding the merger, including the benefits of the merger, revenue opportunities, anticipated future financial and operating performance, and results, including estimates for growth, and the expected timing of the merger. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vyome's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (a) the occurrence of any event, change, or other circumstances that could give rise to the termination of the merger; (b) failure to obtain the necessary consents and approvals, including the approval of ReShape's stockholders; (c) the inability to complete the merger or satisfy other closing conditions; (d) the risk that the merger disrupts current plans and operations as a result of the announcement and consummation of the merger; (e) the approval of the continued listing application of ReShape to have the common stock of the combined company continue to be traded on Nasdaq; (f) costs related to the merger; and (g) changes in applicable laws or regulations. Vyome cautions that the foregoing list of factors is not exhaustive. Vyome cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vyome does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, whether as a result of new information, future events, or otherwise, except as may be required by applicable law.
